



## Curriculum Vitae

*Francesco Fabbri*

### Personal Information

Name	<b>Fabbri Francesco</b>
Home address	Via San Marino, 5 – 48018 Faenza (RA) - Italy
Telephone	39 0543 739230 – 39 0543 739977
FAX	39 0543 / 739221
Mobile phone	349 536 3197
e-mail	<a href="mailto:francesco.fabbri@irst.emr.it">francesco.fabbri@irst.emr.it</a>
Nationality	Italian
Date and place of birth	23.12.1976 - Faenza (RA) - Italy
	FBBFNC76T23D458T

Type of business or sector	<b>Research Biologist (Pre-Clinical Oncology), MS, PhD (Molecular Medicine, 2015)</b>
	 <b>Citation Index: 1005</b>
	 <b>H-Index: 20 / Total citations: 1005 (SCOPUS, 30.08.19)</b>
	<b>Documents by author, 47</b>

### WORK EXPERIENCE

Dates	<b>January 2019 - Now</b>
Occupation or position held	Full-time Senior Research Biologist – Researcher & Research Coordinator
Main activities and responsibilities	In charge of the Nanobiomics and Liquid Niche Unit, part of the Biosciences <b>Laboratory</b> of Romagna Cancer Institute and coordinator of a number of research projects (i.e. <i>Disseminazione E Isolamento Ex Vivo Di Cellule Tumorali E Determinanti Biologici Di Metastatzizzazione: Staminalità Tumorale, Transizione Epitelio Mesenchima E Target Terapeutici Personalizzati Nelle Ctc, Caratteristiche molecolari delle CTC come fattore prognostico e predittivo rispetto all'invasione peri-tumorale e ad altre caratteristiche cliniche in pazienti con carcinoma della mammella in stadio precoce, CTC Investigation in esophageal cancer, CLEAR, Investigazione preliminare mediante nuova metodica di cattura delle CTC in vivo and Study of the molecular profile of circulating tumor cells in metastatic colon cancer patients</i> )
Name of employer	Romagna Cancer Institute (I.R.S.T.), Via Maroncelli 40, Meldola - Forlì (FC) ITALY
Type of business or sector	Pre-clinical and translational oncology research

Dates	<b>February 2008 - 2017</b>
Occupation or position held	Full-time Senior Research Biologist (level 3) – Researcher & Scientific Manager
Main activities and responsibilities	In charge of the CTC & Flow-Cytometry laboratory, part of the Biosciences Laboratory of Romagna Cancer Institute and coordinator of a number of research projects (i.e. <i>Disseminazione E Isolamento Ex Vivo Di Cellule Tumorali E Determinanti Biologici Di Metastatzizzazione: Staminalità Tumorale, Transizione Epitelio Mesenchima E Target Terapeutici Personalizzati Nelle Ctc, Caratteristiche molecolari delle CTC come fattore prognostico e predittivo rispetto all'invasione peri-tumorale e ad altre caratteristiche cliniche in pazienti con carcinoma della mammella in stadio precoce, CTC Investigation in esophageal cancer, Ricerca di Cellule Tumorali Circolanti EML4-ALK positive in pazienti con tumore del polmone metastatico: investigazione preliminare mediante nuova metodica di cattura delle CTC in vivo and Study of the molecular profile of circulating tumor cells in metastatic colon cancer patients</i> )
Name of employer	Romagna Cancer Institute (I.R.S.T.), Via Maroncelli 40, Meldola - Forlì (FC) ITALY

Type of business or sector	Pre-clinical and translational <b>oncology</b> research
Dates	<b>February 2008 – August 2015</b>
Occupation or position held	Full-time Senior Research <b>Biologist</b> (level D3) – Research technician
Main activities and responsibilities	In charge of the Flow-Cytometry laboratory, part of the Biosciences Laboratory of Romagna Cancer Institute and coordinator of a number of research projects (i.e. <i>Disseminazione E Isolamento Ex Vivo Di Cellule Tumorali E Determinanti Biologici Di Metastatizzazione: Staminalità Tumorale, Transizione Epitelio Mesenchima E Target Terapeutici Personalizzati Nelle Ctc, Caratteristiche molecolari delle CTC come fattore prognostico e predittivo rispetto all'invasione peri-tumorale e ad altre caratteristiche cliniche in pazienti con carcinoma della mammella in stadio precoce, CTC Investigation in esophageal cancer, Ricerca di Cellule Tumorali Circolanti EML4-ALK positive in pazienti con tumore del polmone metastatico: investigazione preliminare mediante nuova metodica di cattura delle CTC in vivo and Study of the molecular profile of circulating tumor cells in metastatic colon cancer patients</i> )
Name of employer	Romagna Cancer Institute (I.R.S.T.), Via Maroncelli 40, Meldola - Forlì (FC) ITALY
Type of business or sector	Pre-clinical and translational oncology research
Dates	<b>May 2006 - January 2008</b>
Occupation or position held	Freelance Research Biologist
Main activities and responsibilities	Coordinator of the research project <i>Global Project Prostate</i>
Name of employer	Istituto Oncologico Romagnolo (I.O.R.), C.so Mazzini 65, Forlì (FC) ITALY
Type of business or sector	Pre-clinical and translational oncology research
Dates	<b>May 2005 - April 2006</b>
Occupation or position held	Freelance Research Biologist
Main activities and responsibilities	Coordinator of the research project <i>Global Project Prostate</i>
Name of employer	Azienda Unità Sanitaria Locale, C.so della Repubblica 171/D, 47100 (FC), ITALY
Type of business or sector	Pre-clinical and translational oncology research
Dates	<b>January 2003 - December 2004</b>
Occupation or position held	Contract Research Biologist
Main activities and responsibilities	Coordinator of the research project, <i>Identification of molecules involved in oxidative stress: targets for anticancer therapy</i>
Name of employer	Azienda Unità Sanitaria Locale, C.so della Repubblica 171/D, 47100 (FC), ITALY
Type of business or sector	Pre-clinical and translational <b>oncology</b> research
Dates	<b>January 2002 – December 2002</b>
Occupation or position held	Contract Research Biologist (grant)
Main activities and responsibilities	Coordinator of the research project, <i>Investigation of new anticancer drugs for the treatment of gastric cancer</i>
Name of employer	Azienda Unità Sanitaria Locale, C.so della Repubblica 171/D, 47100 (FC), ITALY - "Fondazione Taccia - Ricerca sul Cancro" grant (Rimini, Italy)
Type of business or sector	Pre-clinical and translational oncology research
Dates	<b>October 2001 – December 2001</b>

*Giancarlo Fokm*

Occupation or position held	Volunteer
Main activities and responsibilities	Pre-clinical and translational oncology research
Name of employer	Azienda Unità Sanitaria Locale, C.so della Repubblica 171/D, 47100 (FC), ITALY
Type of business or sector	Pre-clinical and translational oncology research
Dates	<b>January 2000 - July 2001</b>
Occupation or position held	Internship for experimental degree thesis
Main activities and responsibilities	Biomolecular research on the interaction between proteins of the vitellin membrane proteins in drosophila melanogaster
Name of employer	Biomolecular Genetics Laboratory directed by Prof. Giuseppe Gargiulo; Faculty of Science, Bologna University; Experimental and Evolutionary Department, via Selmi 5, Bologna, ITALY
Type of business or sector	Molecular genetics research
Dates	<b>September 1995</b>
Occupation or position held	Student
Main activities and responsibilities	Six-week practical training period in the area of carcinogenesis in experimental animals
Name of employer	Istituto Oncologico Ramazzini - Bentivoglio Castle, Bentivoglio (BO) - ITALY
Type of business or sector	Pre-clinical research into carcinogenesis
<b>Education and training</b>	
Dates	<b>From November 2010 to 2014 - PhD in Molecular Medicine and Immunological Sciences</b>
Name and type of organisation providing education and training	University of Turin – Doctoral School of Health and Life Sciences – PhD program in Molecular Medicine and Immunological Sciences
Principal topics and professional skills acquired	Doctoral Studentship in Molecular Medicine. Title: "Identification And Study Of Circulating Tumor Cells From Peripheral Blood Of Patients With Early And Metastatic Cancer: Genotypic, Phenotypic And Functional Heterogeneity"
Dates	<b>October 2005</b>
Name and type of organisation providing education and training	Italian Cytometry Group - Gruppo Italiano di Citofluorimetria (G.I.C.) - Faculty of Science, Urbino University
Principal topics and professional skills acquired	Practical training in " <u>Application of Flow-cytometry in Onco-hematology</u> "
Dates	<b>November 2004</b>
Name and type of organisation providing education and training	Faculty of Science, Bologna University
Principal topics and professional skills acquired	Degree in Applied Genetics; main title of thesis: "Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells". Practical training in flow-cytometry and pre-clinical pharmacology experimentations.
Title of qualification awarded	Graduate studies on Applied Genetics; Final exam result: 70 / 70 cum laude



Livello nella classificazione nazionale o internazionale

Qualification to work as a biologist

Dates

**October 2004**

Name and type of organisation providing education and training

Italian Cytometry Group - Gruppo Italiano di Citofluorimetria (G.I.C.) - Faculty of Science, Urbino University

Principal topics and professional skills acquired

Practical training in "Flow-activated and immune-magnetic cell sorting"

Dates

**From November 2002 to March 2003**

Name and type of organisation providing education and training

Faculty of Science, Milan University

Principal topics and professional skills acquired

Principles and techniques in Flow Cytometry

Title of qualification awarded

First level Masters Degree in Flow Cytometry



Dates

**October 2002**

Name and type of organisation providing education and training

Italian Cytometry Group - Gruppo Italiano di Citofluorimetria (G.I.C.) - Faculty of Science, Urbino University

Principal topics and professional skills acquired

Practical and theoretical training in "Cellular proliferation and apoptosis"

Dates

**October 2002**

Name and type of organisation providing education and training

Registration with National Biology Register

Principal topics and professional skills acquired

Qualification as Professional Biologist

Title of qualification awarded

National Order of Biologists - Ordine Nazionale Biologi (O.N.B.), via Icilio 7, Roma, ITALIA

Dates

**From 1995 to 2001**

Name and type of organisation providing education and training

Faculty of Science, University of Bologna, Bologna

Principal topics and professional skills acquired

Molecular genetics – Title of thesis: Role of the VM32E protein in the formation of the vitellin membrane of drosophila melanogaster

Title of qualification awarded

5-year Degree in Biology with specialization in Molecular Biology; final exam result: 110 / 110 cum laude

Level in national classification

5A

Dates

**From 1990 to 1995**

Name and type of organisation providing education and training

Liceo Scientifico F. Severi, Faenza

Title of qualification awarded

High school diploma (Maturità) specializing in scientific subjects; Final exam result 56 / 60

Level in national  
classification

3A

## PERSONAL SKILLS AND COMPETENCES

Mother tongue

Italian



Other languages

English

Comprehension		Spoken		Writing
Listening	Reading	Interaction	Production	Good
Good	Good	Good	Good	

Technical Skills

- Use of FACS Vantage cell-sorter cytofluorimeter
- Use of FACS Canto (A) cytofluorimeter
- Use of DepArray (rare cell population sorter, i.e., circulating tumor cells, cancer stem cells)
- Immuno-phenotyping
- Apoptosis evaluation:
  - TUNEL assay
  - Annexin-V assay
  - JC-1 assay
  - Hypo-diploid peak test
- Cytofluorimetric evaluation of cell cycle by
  - Propidium iodide staining
  - BrdU assay
  - EdU kit
- Cytofluorimetric evaluation of intracellular calcium concentration
- Cytofluorimetric evaluation of intracellular cytoplasmic proteins
- Cytofluorimetric evaluation of Extracellular Vesicles (EVs)
- EV study via NTA
- Cell Culture
- Fluorescence microscopy
- Cell organelle staining (Golgi apparatus, endoplasmic reticulum, mitochondria)
- Western Blot
- Flow activated and immune-magnetic Cell sorting
- Use of Cell analysis software (FACSDiva, FACSCanto, Cell QuestPro, Modfit)
- Use of standard laboratory instrumentation: centrifuge, microscope, pipettes, etc., ...
- Good knowledge of PC e MACINTOSH OS
- Good knowledge of Microsoft Office and graphic software (MS-Office, Adobe-Photoshop, ...)

I authorize the use of my personal data according to Legislative Decree N°196/03

## PUBLICATIONS

### First author (n° 7)

1. **Fabbri F**, Brigliadori G, Ulivi P, Tesei A, Vannini I, Rosetti M, **Bravaccini S**, Amadori D, Bolla M, and W. Zoli. Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. *Apoptosis*, 10(5) 1095-1104, 2005. - I.F. 4.5
2. F Fabbri, S Carloni, G Brigliadori, W Zoli, R Lapalombella, M Marini. Sequential Events Of Apoptosis Involving Microtubule-Interfering Agents: A Cytometric Study. *BMC Cell Biology*, Jan 26;7:6, 2006. - I.F.: 2,7 2.46
3. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Vannini I, Tesei A, Silvestrini R, Amadori D, Zoli W. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. *J Transl Med*. 2008 Aug 8;6:43. - I.F.: 3,0 3.51
4. Fabbri F, Amadori D, Carloni S, Brigliadori G, Tesei A, Ulivi P, Rosetti M, Vannini I, Arienti C, Zoli W, Silvestrini R. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. *J Cell Physiol*. 2008 Nov;217(2):494-501. - I.F.: 3,7 3.98
5. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Tesei A, Silvestrini R, Amadori D, Zoli W. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. *Prostate*. 2010 Feb 1;70(2):219-27 – I.F.: 3.6 3.37
6. Fabbri F, Zoli W, Carloni S, Ulivi P, Arienti C, Brigliadori G, Montanari M, Tesei A, Silvestrini R, Amadori D. Activity of Different Anthracycline Formulations in Hormone-Refractory Prostate Cancer Cell Lines: Role of Golgi Apparatus. *J Cell Physiol*. 2011 Feb 1. - I.F.: 4.5 3.98
7. Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, Chiadini E, Passardi A, Frassinetti GL, Ragazzini A, Amadori D. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. *Cancer Lett*. 2013 Feb 16. - I.F.: 5.09
8. Fabbri F, Salvi S, Bravaccini S. Know your enemy: Genetics, aging, exposomic and inflammation in the war against triple negative breast cancer. *Semin Cancer Biol*. 2019 Oct 25. pii: S1044-579X(19)30191-9. doi: 10.1016/j.semcancer.2019.10.015 – I.F.: 9.65



**Last author (n° 6)**

9. Roberta Maltoni †, Pietro Fici †, Dino Amadori, Giulia Gallerani, Claudia Cocchi, Martina Zoli, Andrea Rocca, Lorenzo Ceconetto, Secondo Folli, Emanuela Scarpi, Patrizia Serra, **Francesco Fabbri**. Circulating tumor cells in early breast cancer: a connection with vascular invasion. Cancer Lett. [Cancer Lett. 2015; † contributed equally to this work] - I.F.: 5.09
10. Maltoni R, Gallerani G, Fici P, Rocca A, **Fabbri F**. CTCs in early breast cancer: A path worth taking. Cancer Lett. 2016 Jul 1;376(2):205-10. doi: 10.1016/j.canlet.2016.03.051. Epub 2016 Apr 6. PMID: 27060205 - I.F.: 5.09
11. Gallerani G, **Fabbri F**. CTCs in the Adenocarcinoma of the Esophagus. International Journal of Molecular Sciences. In press - I.F.: 3.29
12. Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E, Amadori D, Puisieux A, Rigaud M, **Fabbri F**. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. Oncotarget. 2016 Nov 29. doi: 10.18632/oncotarget.13682
13. Gallerani G, Fici P and **Fabbri F**. Circulating Tumor Cells: Back to the Future. Front. Oncol., 11 January 2017 - <https://doi.org/10.3389/fonc.2016.00275>
14. Gallerani G, Cocchi C, Bocchini M, Piccinini F, **Fabbri F**. Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH. J Vis Exp. 2017 Dec 21;(130). doi: 10.3791/56936
15. Rossi E, **Fabbri F**. CTCs 2020: Great Expectations or Unreasonable Dreams. Cells. 2019 Aug 27;8(9). pii: E989. doi: 10.3390/cells8090989.
16. Adipocytes and microRNAs Crosstalk: A Key Tile in the Mosaic of Breast Cancer Microenvironment. Bandini E, Rossi T, Gallerani G, **Fabbri F**. Cancers (Basel). 2019 Sep 27;11(10). pii: E1451. doi: 10.3390/cancers11101451.



**Co-author (n° 29)**

17. Zoli W, Ricotti L, Tesei A, Ulivi P, Gasperi-Campani A, **Fabbri F**, Gunelli R, Frassinetti GL, Amadori D. Schedule-dependent Cytotoxic interaction between Etoposide and Gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res 10, 1500-1507, 2004. I.F. 5.6

18. A Tesei, P Ulivi, **F Fabbri**, M Rosetti, C Leonetti, M Scarsella, G Zupi, D Amadori, W Zoli . In vitro and in vivo evaluation of NCX 4040 cytotoxic activity on the growth of human colon cancer cell lines. J Transl Med. Feb 2003;3(1):7, 2005. I.F.

2.2

19. Ulivi P, Zoli W, **Fabbri F**, Bigliadori G, Ricotti L, Tesei A, Rosetti M, DeCesare M, Beretta G, Corna E, Supino R, Zunino F. Cellular basis of Antiproliferative and Antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models. Neoplasia Feb 7:2, 152-161. 2005. I.F.: 4.4
20. D Soldateschi, S Bravaccini, B Berti, A Brogi, T Benicchi, C Soldatini, L Medri, **F Fabbri**, F De Paola, D Amadori, D Calistri. Development and Characterization of a Monoclonal Antibody Directed Against Human Telomerase Reverse Transcriptase (hTERT). J Biotechnol, Sep 10;118(4):370-8, 2005. I.F.: 2,3
21. Rosetti M, Tesei A, Ulivi P, **Fabbri F**, Vannini I, Bigliadori G, Granato AM, Amadori D, Zoli W. Modulation of Drug Cytotoxicity by Iressa (ZD1839) in Pancreatic Cancer Cell Lines. Cancer Biol Ther. Oct 7;4(10) 1089-95 2005. I.F. 3.3
22. W Zoli, P Ulivi, A Tesei, **F Fabbri**, Rosetti M, R Maltoni, D Casadei Giunchi, L Ricotti, G Bigliadori, I Vannini, D Amadori. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase- dependent apoptosis in breast cancer cell lines. Breast Cancer Res 7(5), 681-689, 2005. I.F. 3.0
23. Ulivi P, Zoli W, Calistri D, **Fabbri F**, Mengozzi M, Tesei A, Rosetti M, Amadori D. "p16INK4A and CDH13 Hypermethylation in Tumor and Serum of Non-Small Cell Lung Cancer Patients. J Cell Physiol, 206:611-615, 2006. I.F.: 5.2
24. Leonetti C, Scarsella M, Zupi G, Zoli W, Amadori D, Medri L, **Fabbri F**, Rosetti M, Ulivi P, Cecconetto L, Bolla M, Tesei A. Efficacy of a nitric oxide-releasing NSAID and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Apr;5(4):919-26, 2006. I.F. 5.2
25. Rosetti M, Tesei A, Ulivi P, **Fabbri F**, Vannini I, Bigliadori G, Amadori D, Bolla M, Zoli W. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. Apoptosis Aug;11(8):1321-30. 2006. I.F. 4.6
26. Rosetti M, Zoli W, Tesei A, Ulivi P, **Fabbri F**, Vannini I, Bigliadori G, Granato AM, Amadori D, Silvestrini R. Iressa Strengthens the Cytotoxic Effect of Docetaxel in NSCLC Models that Harbor Specific Molecular Characteristics. Journal of Cellular Physiology, Sep;212(3):710-6. 2007. I.F.: 4,4
27. Vannini I, Bonafe M, Tesei A, Rosetti M, **Fabbri F**, Storci G, Ulivi P, Bigliadori G, Amadori D and Zoli W. Short interfering RNA directed against the Slug gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine, Cellular Oncology 29(4):279-87. 2007 I.F.: 4,2

*Francesco Fabbri*



28. Tesei A, Rosetti M, Ulivi P, **Fabbri F**, Medri L, Tannini I, Bolla M, Amadori D, Zoli W. Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. J Transl Med. 2007 Oct 30;5(1):52 I.F. 3,0
29. Passardi A, Maltoni R, Milandri C, Cecconetto L, Massa I, Zoli W, Tesei A, **Fabbri F**, Nanni O, Amadori D. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies. Oncology. 2007;72(1-2):118-24. I.F. 1.8
30. Rosetti M, Frasnelli M, **Fabbri F**, Arienti C, Vannini I, Tesei A, Zoli W and Conti M. Pro-apoptotic Activity of Cyclopentenone in Cancer Cells. Anticancer Res. 2008 Jan-Feb;28(1A):315-20. I.F.: 1,6
31. Tesei A, Wainer Zoli, **Fabbri F**, Carlo Leonetti, Marco Rosetti, Manlio Bolla, Dino Amadori , Rosella Silvestrini. NCX 4040, an NO-donating acetylsalicylic acid derivative: Efficacy and mechanisms of action in cancer cells. Nitric Oxide. 2008 Apr 22. I.F.: 2,5
32. Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfino D, **Fabbri F**, Ulivi P, Brigliadori G, Amadori D, Bonafe M. Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumour Biol. 2008;29(3):145-51. I.F.: 2,5
33. Vannini I, Zoli W, Fabbri F, Ulivi P, Tesei A, Carloni S, Brigliadori G, Amadori D. Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. Anticancer Drugs. 2009 Sep 11. [Epub] – I.F.: 2.3
34. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol. 2009 Jul;220(1):214-2 - I.F.: 3,7
35. Tesei A, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. J Cell Mol Med. 2009 Dec 8 - I.F.: 5.2
36. Carloni S, Fabbri F, Brigliadori G, Ulivi P, Silvestrini R, Amadori D, Zoli W. Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells. Curr Cancer Drug Targets. 2010 Apr 12. IF: 4.3.
37. Ulivi P, Arienti C, Zoli W, Scarsella M, Carloni S, Fabbri F, Tesei A, Chiadini E, Orlandi A, Passeri D, Zupi G, Milandri C, Silvestrini R, Amadori D, Leonetti C. In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells. Curr Cancer Drug Targets. 2010 May 21 - I.F.: 4.3

*Francesco Fabbri*

38. Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. *Cancer Cell Int.* 2012 Nov 22;12(1):48. (I.F.: 1.973; IF norm MS: 2).
39. Tesei A, Brigliadori G, Carloni S, Fabbri F, Ulivi P, Arienti C, Sparatore A, Del Soldato P, Pasini A, Amadori D, Silvestrini R, Zoli W. Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. *J Cell Physiol.* 2012 Oct; 227(10):3389-96. (I.F.: 3.986; IF norm MS: 6).
40. Montanari M, Fabbri F, Rondini E, Frassinetti GL, Mattioli R, Carloni S, Scarpi E, Zoli W, Amadori D, and Cruciani G. Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. *Tumori*, 98: 696-701, 2012. (I.F.: 0.86; IF norm MS: 1).
41. Burgio SL, Fabbri F, Seymour IJ, Zoli W, Amadori D, De Giorgi U. Perspectives on mTOR inhibitors for castration-refractory prostate cancer. *Curr Cancer Drug Targets.* 2012 Oct;12(8):940-9. (I.F.: 4.327; IF norm MS: 6).
42. Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. *Int J Oncol.* 2013 Apr;42(4):1263-70. doi: 10.3892/ijo.2013.1809. Epub 2013 Feb 6. 2.657 (I.F.: 2.657)
43. Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, Liverani C, Zanoni M, Zoli W, Maltoni R, Gunelli E, Amadori D, Ibrahim T. RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study. *Int J Mol Sci.* 2013 May 23 (I.F.: 2.464)
44. Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. *Bone.* 2014 (I.F.: 4.461)
45. Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Barriere G, Fici P, Gallerani G, Fabbri F, Zoli W, Rigaud M. (Review) *Annals of Translational Medicine*, Oct 2014 (I.F.: waiting)
46. Barriere G, Fici P, Gallerani G, Fabbri F, Rigaud M. Epithelial Mesenchymal Transition: a double-edged sword. *Clin Transl Med.* 2015 Apr 14;4:14. doi: 10.1186/s40169-015-0055-4.

*Francesco Fabbri*

## Congress presentations (n° 44)

1. Zoli W, Tesei A, Ulivi P, **Fabbri F**, Rosetti M, Brigliadori G. L'utilizzo di un nuovo anti-infiammatorio non steroideo (NCX4040) potenzia, su linee cellulari di carcinoma del colon, l'attività citotossica di Oxaliplatino. Eloxatin Meeting, Milano 17-19 marzo 2004.
2. Tesei A, Ulivi P, **Fabbri F**, Rosetti M, Brigliadori G. COX-2 independent cytotoxic activity of NCX4040, a nitric oxide-releasing aspirin derivative, in human colon cancer cell lines. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers, Brussels, Belgium, J Biol Marker, 19, S3, April 18-20, 2004.
3. Petrini M, Riccobon A, Fiorentini G, Stefanelli M, Fiammenghi L, Giorgetti G, **Fabbri F**, Ridolfi L, Ridolfi R. Characterization of in vitro dendritic cells transiently exposed to maturation stimuli. "ICIS-FOCIS" Montreal, Luglio 2004.
4. C Leonetti, M Scarsella, G Zupi, W Zoli, D Amadori, P Ulivi, **F Fabbri**, A Tesei. In vitro and in vivo antitumor efficacy of NCX 4040, a nitric oxide-releasing non steroidal anti-inflammatory drug, in combination with antineoplastic drugs on human colon cancer lines. 16th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics". Geneva, Switzerland, 28 settembre - 1 ottobre 2004.
5. Tesei A, P Ulivi, **F Fabbri**, C Leonetti, M Scarsella, G Zupi, D Amadori, W Zoli. Apoptosis induced by NCX 4040, a nitric oxide-releasing aspirin derivative, in human colon cancer cell lines. 16th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics". Geneva, Switzerland, 28 settembre - 1 ottobre 2004.
6. Rosetti M, Tesei A, Ulivi P, **Fabbri F**, Vannini I, Brigliadori G, Bravaccini S, Amadori D, Bolla M, Zoli W. Molecular characterization of cytotoxic and drug resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics- 14-18 nov 2005.
7. Rosetti M, Tesei A, Ulivi P, Vannini I, **Fabbri F**, Brigliadori G, Bravaccini S, Amadori D, Zoli W. Evaluation of drug interaction between docetaxel and gefitinib in three human non-small cell lung cancer (NSCLC) cell lines. I supplementi di Tumori, 2006.
8. **Fabbri F**. Attività e meccanismi di azione del Docetaxel. Presentazione orale al congresso I.O.R. / I.R.S.T. "Docetaxel: Stato dell'Arte e Prospettive", Forlì, 16 marzo 2007. - **Presentazione orale**
9. Vannini I, Bonafe M, Tesei A, Rosetti M, **Fabbri F**, Storci G, Ridolfi R, Ulivi P, Brigliadori G, Amadori D, Zoli W. Short interfering RNA directed against the SLUG gene increases the sensitivity of human melanoma cell lines to cytotoxic drugs 4<sup>th</sup> Research meeting on melanoma IEO 10-11 may 2007

*Francesco Fabbri*

10. Tesei A., Rosetti M, Ulivi P, **Fabbri F**, Medri L, Vannini I, Bolla M, Amadori D, Zoli W Study of molecular mechanism of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines Focus on innovative locoregional oncotherapies Mirandola (Modena) 19-20 nov 2007
11. **F. Fabbri**, D. Amadori, S. Carloni, G. Brigliadori, A. Tesei, P. Ulivi, M. Rosetti, I. Vannini, C. Arienti, W. Zoli and R. Silvestrini. Role of mitotic catastrophe, p21 and caspase-2 expression in docetaxel- induced apoptosis in hormone refractory prostate cancer cells. PAMM-EORTC Congress, Palermo, Gennaio 2008. - **Poster**
12. **F. Fabbri**, D. Amadori, S. Carloni, G. Brigliadori, A. Tesei, P. Ulivi, I. Vannini, C. Arienti, W. Zoli and R. Silvestrini. Zoledronic acid enhances Docetaxel induced apoptosis through pMEK and MCL-1 inhibition in hormone sensitive prostate carcinoma cell lines. AACR Congress, San Diego, Aprile 2008 – **Poster**
13. **F. Fabbri**, G. Brigliadori, S. Carloni, P. Ulivi, I. Vannini, A. Tesei, R. Silvestrini, D. Amadori, and W. Zoli. Zoledronic acid induced inhibition of pMEK, Mcl-1 and p21 enhances Docetaxel cytotoxicity in a hormone sensitive prostate carcinoma model. First International Congress in Translational Medicine, Forlì, Maggio 2008 - **Poster**
14. R. Gunelli, **F. Fabbri**, D. Amadori, S. Carloni, G. Brigliadori, A. Tesei, P. Ulivi, I. Vannini, C. Arienti, W. Zoli and R. Silvestrini. Zometa increases Docetaxel induced apoptosis in the hormone sensitive prostate carcinoma cell line LNCaP. Congresso AURO 2008
15. **Fabbri F**. Attività in vitro di Doxorubicina e sue diverse formulazioni nel Carcinoma della Prostata Ormono-Resistente. al Congresso I.R.S.T. "Terapia medica del carcinoma prostatico tra presente e prospettive future", Meldola, 6 settembre 2008 - **Presentazione orale**
16. **Fabbri F**. Docetaxel e Acido Zoledronico nel Carcinoma della Prostata Ormono-sensibile: le indicazioni che nascono dalla pre-clinica. Congresso I.R.S.T. "Terapia medica del carcinoma prostatico tra presente e prospettive future", Meldola, 6 settembre 2008 - **Presentazione orale**
17. **Fabbri F**, Brigliadori G, Carloni S, Montanari M, Frassinetti GL, Amadori D, Zoli W. "Activity of different doxorubicin formulations In hormone-refractory prostate cancer (HRPC) cell lines." Conferenza Nazionale AIOM 11-14 Verona ottobre 2008
18. **Fabbri F** "Meccanismi di farmaco – resistenza e loro possibile superamento" - Conferenza Nuove Opportunità. Nel Trattamento Chemioterapico Del Carcinoma Mammario - 24 gennaio 2009 - **Presentazione orale**
19. **Fabbri F**, M Montanari, G Cruciani, D Amadori, W Zoli Translational study on the activity of liposomal doxorubicin formulations in hormone-refractory prostate cancer (HRPC). ASCO 2009 (electronic abstract: ASCO n°: e16026)
20. **Fabbri F** "Attività in vitro di Doxorubicina Liposomiale non Pegilata nel Carcinoma della Prostata Ormono-Resistente" – presentazione orale - Ravenna, mercoledì 4 marzo 2009 – **Presentazione orale**

*francesco fabbri*

21. **Fabbri F**, S Carloni, G Brigliadori, E Bandini, P Ulivia, R Silvestrini, D Amadori, W Zoli. Gefitinib, lapatinib and sorafenib alter cytosolic calcium concentration and xenobiotic extrusion activity in breast cancer cells. 14th World Congress on Advances in Oncology and 12th International Symposium on Molecular Medicine October 15-17, 2009 – Lutraki – Greece

**Presentazione orale**

22. **Fabbri F**, Carloni S., Brigliadori G., Ulivi P., Tesei A., Montanari M., Amadori D., Silvestrini R., Zoli W. **Liposomal** doxorubicin induces Golgi-dependent apoptosis in hormone-refractory prostate cancer cell lines (HRPC). Abstract A83: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 15-19 Nov 2009, Boston, MA – **POSTER**. **ABSTRACT** Pubblicato su Molecular Cancer Therapeutics Volume 8, Issue 12, Supplement 1 a December 10, 2009.
23. Carloni S., **Fabbri F**, Brigliadori G., Ulivi P., Amadori D., Silvestrini R., Zoli W. Tyrosine kinase inhibitors induce rapid cellular alterations in breast cancer cells in vitro. Abstract B262: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 15-19 Nov 2009, Boston, MA – **POSTER**. **ABSTRACT** Pubblicato su Molecular Cancer Therapeutics Volume 8, Issue 12, Supplement 1 a December 10, 2009.
24. **Fabbri F**, Carloni S., Brigliadori G., Ulivi P., Tesei A., Montanari M., Amadori D., Silvestrini R., Zoli W. Ruolo dell'apparato del Golgi nell'apoptosi indotta da doxorubicina liposomiale non pegilata in cellule di carcinoma della prostata ormono-refrattario. Convegno Annuale della Associazione Italiana di Colture Cellulari (ONLUS-AICC) - LA MORTE DELLA CELLULA: implicazioni fisio-patologiche e terapeutiche Firenze, 2-4 dicembre 2009 – **Presentazione orale e poster**
25. Montanari M, **Fabbri F**, Frassinetti GL, Rondini E, Mattioli R, Luzi Fedeli S, Carloni S, Zoli W, Amadori D, Cruciani G. Phase II trial of non pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: a translational study. ASCO 2010 . 4-8 Jun 2010, Chicago, IL – **Presentazione POSTER**
26. Mercatali L, Ibrahim T, Sacanna E, Scarpi E, **Fabbri F**, Ricci R, Calistri D, Amadori D. A new panel of tissue markers for the prediction of bone metastatization from primary breast cancer AACR Congress, Orlando, Aprile 2011 – **Poster**
27. **Fabbri F**, Carloni S, Ulivi P, Mercatali L, Milandri C, Ricci M, Amadori D, Zoli W. Preliminary investigation of circulating NSCLC cells using dielectrophoresis-based instrumentation. AACR Congress, Orlando, Aprile 2011 – **Poster**
28. Investigation of circulating colon and lung cancer cells using a dielectrophoresis-based instrumentation. **Fabbri F**, S. Carloni, P. Ulivi, G. Gallerani, P. Fici, E. Chiadini, A. Passardi, D. Amadori, W. Zoli - Congresso CTC Conference and Exhibition, San Diego, Feb 2012 – **Poster**
29. Isolation of living circulating tumor cells using dielectrophoresis-based instrumentation. S. Carloni, F. Fanini, G. Gallerani, E. Bandini, S. Pignatta, **F. Fabbri**, G. Brigliadori, D. Amadori, W. Zoli Congresso CTC Conference and Exhibition, San Diego, Feb 2012 – **Poster**

*F. Fabbri*

30. Circulating colon and lung cancer cell heterogeneity. **Francesco Fabbri**<sup>1</sup>, Paola Ulivi<sup>1</sup>, Giulia Gallerani<sup>2</sup>, Pietro Fici<sup>3</sup>, Elisa Chiadini<sup>1</sup>, Dino Amadori<sup>1</sup>, Wainer Zoli<sup>1</sup> <sup>1</sup>Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy; <sup>2</sup>Department of Internal Medicine, Aging and Renal Disease, University of Bologna, Section of Nephrology, Dialysis and Transplantation, Bologna, Italy; <sup>3</sup>Department of Medical and Surgical Sciences (DIMEC), and Pathology Unit, Felice Addarii Institute, University of Bologna, Italy. ISMRC 2013, Sept 2013, Paris – **Poster**
31. A multi-parametric prospect/approach to pinpoint heterogenic circulating tumor cells. Giulia Gallerani<sup>1</sup>, Pietro Fici<sup>2</sup>, Dino Amadori<sup>3</sup>, Wainer Zoli<sup>3</sup>, **Francesco Fabbri**<sup>3</sup>; <sup>1</sup>Department of Medical and Surgical Sciences (DIMEC), and Pathology Unit, Felice Addarii Institute, University of Bologna, Italy; <sup>2</sup>Department of Internal Medicine, Aging and Renal Disease, University of Bologna, Section of Nephrology, Dialysis and Transplantation, Bologna, Italy; <sup>3</sup>Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy. ISMRC 2013, Sept 2013, Paris – **Poster**
32. CTCc and EMT Identification by DEParay & Gene Expression by RT-qPCR. **Fabbri F**, Fici P, Gallerani G, Rigaud M, Zoli W, Amadori D. Circulate 2014, Circulating Cancer Biomarkers Europe 2014, Berlin 18 – 21 Feb 2014 – **Oral Presentation**.
33. EMT ratio as CTC aggressiveness index. Fici P, Gallerani G, Rigaud M, **Fabbri F**. 9th International Conference of Anticancer Research 6-10 October 2014. P. Carras Grand Resort, Sithonia, Halkidiki, Greece. – **Oral Presentation**.
34. Gallerani G, Zoli M, Fici P, Bravaccini S, Tumedei M, Delmonte A, Burgio MA, Casadei C, **Fabbri F**. 9th International Conference of Anticancer Research. Porto Carras Grand Resort, Sithonia, Halkidiki, Greece, 6 - 7 October, 2014 – **Oral Presentation**.
35. EML4-ALK status investigation in CTCs in NSCLC advanced adeno-carcinoma patients: preliminary investigation using an in vivo procedure. Gallerani G, Zoli M, Fici P, Bravaccini S, Tumedei M, Delmonte A, Burgio MA, Casadei C, **Fabbri F**. Advances in CTC 2014, From Basic Research to Clinical Practice, (ACTC 2014). October 8th –11th, 2014, Crete, Greece – **POSTER**
36. The grab all-assay: a multi-parametric approach to identify heterogeneous circulating tumor cells. Gallerani G, Pietro Fici P, Valgiusti M, Amadori D, Mattioli S, **Fabbri F**. Congress of the European Society for the Diseases of the Esophagus, 20 – 22 Nov 2014, Bologna, Italy. - **POSTER**

*Francesco Fabbri*

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 675/96 del 31 dicembre 1996.